ArticleDiscover oncology2025
lncRNA ACVR2B-AS1 modulates thyroid cancer progression by regulating miR-195-5p.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
- Exploring shared biomarkers and their mechanisms in thyroid cancer and systemic lupus erythematosus via bioinformatics analysis.Discover oncology · 2026Article
- The Interplay Between lncRNAs-microRNAs Network Dysregulation and Cellular Hallmarks of Thyroid Cancer.Cancers · 2025Review
- Silencing MMP2-AS1 inhibits the proliferation and migration of endothelial cells via YB-1.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundlncRNAs are key regulators in thyroid cancer (TC). While lncRNA ACVR2B-AS1 has been proposed as a potential TC biomarker, its role remains underexplored. This study aims to clarify its clinical significance in TC and investigate its molecular mechanism. MATERIALS AND
methodsqRT-PCR was used to assess the expression of ACVR2B-AS1 in TC tissues and cell lines. Kaplan-Meier survival curves and Cox regression were utilized to assess the prognostic value of ACVR2B-AS1 expression. The interaction between ACVR2B-AS1 and miR-195-5p, as well as their effects on cell viability, migration, and invasion, were evaluated using dual-luciferase reporter assays, CCK-8 assays, and Transwell assays.
resultsACVR2B-AS1 was significantly upregulated in TC tissues and cell lines, and its expression correlated with TNM stage and lymph node metastasis. Elevated ACVR2B-AS1 levels were associated with poor survival outcomes, and it was identified as an independent risk factor for TC progression. A direct regulatory relationship was established between ACVR2B-AS1 and miR-195-5p, with ACVR2B-AS1 negatively regulating miR-195-5p, thereby promoting TC cell proliferation, migration, and invasion. FGF2 was predicted and validated as a target gene of miR-195-5p.
conclusionlncRNA ACVR2B-AS1 shows potential as a prognostic marker in TC and may regulate tumor progression through the miR-195-5p/FGF2 axis, offering new insights for TC diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.